In Brief: IVD compliance policy
This article was originally published in The Gray Sheet
IVD compliance policy: Availability of FDA's draft compliance policy guide on commercialization of in vitro diagnostics labeled for research or investigational use is slated to be announced in the Jan. 5 Federal Register. "Except in specified instances, FDA does not intend to initiate enforcement action for 18 to 30 months" after release of a final CPG against companies surreptitiously commercializing tests by labeling them for investigational or research use "provided the IVD manufacturers...take steps to obtain FDA approval," according to the announcement. Required steps "include undertaking, by six months" from publication of the final CPG, "any necessary clinical investigations or other studies."...
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.